Literature DB >> 28682125

Combined surgical and endovascular approach for treatment of aggressive vertebral haemangiomas.

Daniel G Eichberg1, Robert M Starke1, Allan D Levi1.   

Abstract

OBJECTIVE: To analyze the endovascular, surgical, and clinical outcomes of patients with aggressive vertebral haemangiomas (VHs) treated over a 17 year period.
METHODS: All medical, radiological, and surgical records were reviewed retrospectively. All patients underwent follow-up evaluation for pain and neurological outcome.
RESULTS: A total of 10 patients diagnosed with aggressive VHs causing neurologic compromise or pain underwent 13 operative procedures for tumour resection/stabilization. All but one patient underwent preoperative procedures to minimize intraoperative blood loss. Mean follow-up length was 26.3 months. Of eight patients presenting with neurological deficits, all improved postoperatively. The two patients presenting with pain reported improvement postoperatively. Two patients had new postoperative lower extremity weakness, both of which improved during follow-up. One patient experienced tumour recurrence at 1 year, requiring a second staged surgery. A second patient required a staged surgery for resection of multiple VHs. Seven patients had subtotal resections, two patients had gross total resections, and one patient had an en bloc resection of tumour.
CONCLUSIONS: Combined preoperative embolization followed by aggressive tumour resection and spinal stabilization are safe and effective procedures for the treatment of aggressive VH causing symptomatic stenosis.

Entities:  

Keywords:  Vertebral haemangioma; embolisation; fusion; neoplasm; spine; surgery

Mesh:

Year:  2017        PMID: 28682125     DOI: 10.1080/02688697.2017.1344619

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  1 in total

1.  Intraoperative injection of absorbable gelatin sponge (AGS) mixed with cement followed by spinal decompression to treat elderly with vertebral hemangiomas.

Authors:  Weihong Xu; Zhibin Lan; Yuming Huang
Journal:  BMC Musculoskelet Disord       Date:  2020-02-24       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.